Mentions in press and media 14
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Apr 29, 2026 | Coultreon Biopharma Raises $125 Million Series A to Advance Oral Autoimmune Therapy | Coultreon Biopharma, a Belgium-based biotechnology company formerly known as Onco3R Therapeutics, has closed an oversubscribed 125 million dollar Series A financing round to advance its immunology pipeline. The round was led by Sofinnova In... |
| Dec 28, 2025 | Aeovian Pharmaceuticals Secures $55M Series B for Groundbreaking Epilepsy Treatment | Aeovian Pharmaceuticals secured a significant $55 million Series B funding. This pivotal investment propels its lead candidate, AV078, into a Phase 2 study. AV078 is a first-in-class CNS-penetrant selective mTORC1 inhibitor. It targets seve... |
| Dec 27, 2025 | Aeovian Pharmaceuticals: $55 Million Series B Raised To Advance AV078 For Tuberous Sclerosis Complex-Related Refractory Epilepsy | Aeovian Pharmaceuticals, a clinical-stage biopharmaceutical company based in Berkeley, California, has closed an oversubscribed $55 million Series B financing to support completion of a Phase 2 proof-of-concept study for its lead candidate,... |
| Dec 16, 2025 | Aeovian Pharmaceuticals Raises $55M in Funding | Aeovian Pharmaceuticals, a Berkeley, CA-based clinical-stage biopharmaceutical company, raised $55M in funding. The round was led by Luma Group and CTI Life Sciences Fund, with participation from Foresite Capital, SymBiosis, the TSC Allianc... |
| Oct 31, 2025 | Curve Biosciences Ignites New Era in Chronic Disease Care with $40M Funding | Curve Biosciences recently secured $40M in Series A funding. This capital fuels its Whole-Body Intelligence platform. The platform uses the proprietary Whole-Body Atlas, a vast collection of tissue samples. It powers advanced Whole-Body Blo... |
| Oct 30, 2025 | Curve Biosciences: $40 Million Raised To Advance Whole-Body Intelligence Platform for Chronic Disease Monitoring | Curve Biosciences, a biotechnology company pioneering Whole-Body Intelligence for proactive and personalized chronic disease care, has raised $40 million in new funding led by Luma Group, with participation from First Spark Ventures, Techas... |
| Oct 29, 2025 | Curve Biosciences Secures $40M to Launch Whole-Body Intelligence Platform | What You Should Know: – Curve Biosciences, the Whole-Body Intelligence™ company, today announced it has raised $40M in Series A funding led by Luma Group, with participation from First Spark Ventures, Techas Capital, Civilization Ventures, ... |
| Sep 18, 2025 | Character Biosciences Expands Series B Extension | Character Biosciences, Jersey City, NJ-based precision medicine company, raised an undisclosed amount in Series B extension. Backers included Sanofi Ventures. The company intends to use the funds to further advance the clinical development ... |
| Mar 31, 2025 | Character Biosciences: Pioneering Precision Medicine for Eye Diseases | In the realm of healthcare, precision medicine is the compass guiding us toward targeted therapies. Character Biosciences, a New Jersey-based company, is at the forefront of this revolution. Recently, they secured a hefty $93 million in Ser... |
Show more
Reviews 0
FAQ about Luma Group
What has the press written about Luma Group?
Parsers VC has collected 14 articles mentioning Luma Group, among them “Coultreon Biopharma Raises $125 Million Series A to Advance Oral Autoimmune Therapy” (Apr 29, 2026) and “Aeovian Pharmaceuticals Secures $55M Series B for Groundbreaking Epilepsy Treatment” (Dec 28, 2025).
Is Luma Group still active?
Yes, Luma Group is active; its latest activity on Parsers VC dates from Sep 11, 2026.